AlphaNavi Pharma Inc. has established by Kyoto university, Akita university, Sumitomo Dainippon Pharma Co Ltd., and some investors, whose mission is to develop a novel analgesic drug for patients suffering from pain, their families, and medical professionals as soon as possible and to regain the smiles of patients and their families.
In addition to in-house research and clinical development, AlphaNavi Pharma would like to create new values by collaborating with academia, investors, patients, and many supporters in the world.
CEO Yoshihiro Oyamada Ph.D.
Our mission to get patients’ and their family’s
smiles back through the research &
development of innovative novel drugs.
“Alpha” means initial, first, and top. In addition to it, we hope that our novel Nav inhibitors would be sent to patients, who are suffering from rare chronic pain syndrome, to “navigate” them and their families to happiness beyond their smile.
AlphaNavi is named by combining with both alpha and navigate.
|Company||AlphaNavi Pharma Inc.|
|Headquarter||Yoshida-honmachi 36-1, Sakyo-ku, Kyoto, 606-8317|
Kyoto University Venture Incubation Center (KUViC)
> Google map
|Osaka office||Enoki-cho 33-94, Suita,|
> Google map
|Establishment||Jan 29, 2019|